Considerations in Developing a Target Product Profile for Parenteral Pharmaceutical Products
- 15 September 2010
- journal article
- review article
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 11 (3) , 1476-1481
Abstract
A target product profile (TPP) describes how a product will be utilized by the end user. A systematically developed TPP can ensure alignment of objectives across company departments, accelerate development timelines, minimize development risks, and eventually lead to an optimal product. A TPP is particularly important for parenteral products due to the need for administration devices, the variety of possible end users (nurses, patients, pharmacists, and physicians), and requirements specific to sterile products. This manuscript describes key components of a TPP from a formulation development perspective and provides guidance on practical issues common to parenteral products.Keywords
This publication has 11 references indexed in Scilit:
- Target Product Profile: A renaissance for its definition and useJournal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, 2009
- Quality by Design: Concepts for ANDAsThe AAPS Journal, 2008
- Development Pharmaceutics of Microbicide Formulations. Part II: Formulation, Evaluation, and ChallengesAIDS Patient Care and STDs, 2003
- Parenteral formulations of small molecules therapeutics marketed in the United States (1999)--Part I.2001
- Parenteral formulations of small molecules therapeutics marketed in the United States (1999). Part III.2000
- Compendium of excipients for parenteral formulations.1998
- Human behaviour, cost-effectiveness analysis and research and development priorities: the case of a schistosomiasis vaccine.1997
- Comparison of Visual and Turbidimetric Methods for Determining Short-term Compatibility of Intravenous Critical-care DrugsAmerican Journal of Health-System Pharmacy, 1988
- Review of excipients and pH's for parenteral products used in the United States.1980
- Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixturesAmerican Journal of Health-System Pharmacy, 1976